Identification of Molecular Biomarkers for Cancer Target Therapy Efficacy

Status unconfirmed

Conditions studied: Cancer

In brief

This is a prospective trial for a computation-based efficacy prediction method for anticancer target therapies. The original computational algorithm utilizes individual transcriptome data of a cancer sample and assesses changes at the level of gene expression and intracellular signaling pathways. By applying the database of known molecular targets of anticancer target drugs it allows to rank potential efficacies of target drugs.

Key facts

Study ID
NCT03724097
Run by
OmicsWay Corp.
People needed
200
Starts
2017-10-17
Expected to finish
2022-11-01
Last updated by the study team
2021-09-14

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.